COMMUNITY

ÃÖ°íÀÇ ±â¼ú·Â°ú ÃÖ»óÀÇ Ç°Áú,
ÂøÇÑ °¡°ÝÀ¸·Î º¸´äÇÏ¿© µå¸®°Ú½À´Ï´Ù.

Ä¿¹Â´ÏƼ
Community

  • Ȩ
  • Ä¿¹Â´ÏƼ
  • ÇÁ·Î¸ð¼Ç

ÇÁ·Î¸ð¼Ç

ÇÑÁ¤±â°£ ¾Æ¹Ù¹ÙÀÌ¿À Á¦°øÇϴ Ưº°ÇÑ °¡°Ý
Á¦¸ñ [Cusabio] CLDN6, the "New Favorite" in Targeted Cancer Therapy after CLDN 18.2
ÀÛ¼ºÀÚ abbabio
ÀÛ¼ºÀÏÀÚ 2022-07-21
Á¶È¸¼ö 261
If you are unable to see the message below, click here to view.

Claudin-6 (CLDN6), one of Claudins members, is an important molecule that makes up the tight junctions between cells. Claudins members have diverse __expression__ properties. A large amount of research data in recent years reveals that abnormal __expression__ of Claudins is associated with a variety of tumors. CLDN1 abnormal __expression__ can lead to sclerosing cholangitis and ichthyosis. CLDN3 increased __expression__ is associated with reduced alveolar barrier function. CLDN18.2 have become a must-have target for pharmaceutical companies. CLDN6, as the "New Favorite" of claudins family, is also a promising target for cancer drug research! (Read more about CLDN6)

Lately, the 2022-AACR conference saw that the companies such as BioNTech, Amgen, and IMAB have disclosed the progress of CLDN6 targets in their pipeline. the clinical data of BNT-211 (CLDN6 CAR-T) from Germany's BioNTech showed the good tolerability both alone or in combination with vaccines. A bispecific antibodyTJ-C64B (CLDN6 x TNFRSF9) from China's IMAB possesses potent tumor suppressive activity and can specifically activate immunity in the tumor microenvironment without significant risk of hepatotoxicity (Read about CLDN6 clinical research progress).

To fully serve pharmaceutical companies in their CLDN6 based drug research for tumors or other diseases, CUSABIO has launched CLDN6-VLPs active protein product (Code: CSB-MP005508HU(A4)) to help your research on CLDN6 mechanism or its potential clinical applications.

Recombinant Human Claudin-6(CLDN6)-VLPs (Active) In Stock

High Specifity Validated by Western Blot

Excellent Bioactivity Validated by Functional ELISA

TEM

The specifity was validated by western blot. CSB-MP005508HU(A4) is detected by Mouse anti-6*His monoclonal antibody.

Immobilized Human CLDN6 at 10 ¥ìg/ml can bind Anti-CLDN6/9 recombinant antibody (CSB-RA005508MA1HU), the EC50 is 1.501-2.035 ng/mL

The presence of VLP-like structures was confirmed by TEM

CUSABIO appreciates the critical role that you and our products play in research since many scientists are diligently pursuing their research to further scientific innovation and discovery. Our customer service and technical support teams are equipped to remain available to help with your research needs and answer any questions.

Kit
Protein
Antibody
Molecular Biology
CUSABIO TECHNOLOGY LLC
Postal Address: 7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Website: www.cusabio.com
© 2022 CUSABIO All Products For Research Use Only
÷ºÎÆÄÀÏ